- Home
- RLGT vs IMMP Comparison
RLGT vs IMMP Comparison
Compare RLGT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- IMMP
- Stock Information
- Founded
- RLGT 2001
- IMMP 1987
- Country
- RLGT United States
- IMMP Australia
- Employees
- RLGT N/A
- IMMP N/A
- Industry
- RLGT Oil Refining/Marketing
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- RLGT Consumer Discretionary
- IMMP Health Care
- Exchange
- RLGT Nasdaq
- IMMP Nasdaq
- Market Cap
- RLGT 282.9M
- IMMP 251.8M
- IPO Year
- RLGT N/A
- IMMP N/A
- Fundamental
- Price
- RLGT $6.08
- IMMP $2.08
- Analyst Decision
- RLGT Strong Buy
- IMMP Buy
- Analyst Count
- RLGT 1
- IMMP 1
- Target Price
- RLGT $8.00
- IMMP $7.00
- AVG Volume (30 Days)
- RLGT 303.6K
- IMMP 133.3K
- Earning Date
- RLGT 11-11-2025
- IMMP 10-10-2025
- Dividend Yield
- RLGT N/A
- IMMP N/A
- EPS Growth
- RLGT 118.75
- IMMP N/A
- EPS
- RLGT 0.35
- IMMP N/A
- Revenue
- RLGT $902,696,000.00
- IMMP $3,306,742.00
- Revenue This Year
- RLGT $2.96
- IMMP $16.82
- Revenue Next Year
- RLGT $2.98
- IMMP N/A
- P/E Ratio
- RLGT $17.03
- IMMP N/A
- Revenue Growth
- RLGT 12.49
- IMMP 31.28
- 52 Week Low
- RLGT $5.44
- IMMP $1.32
- 52 Week High
- RLGT $7.94
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- RLGT 51.74
- IMMP 69.05
- Support Level
- RLGT $5.82
- IMMP $1.92
- Resistance Level
- RLGT $6.17
- IMMP $2.09
- Average True Range (ATR)
- RLGT 0.15
- IMMP 0.10
- MACD
- RLGT 0.01
- IMMP 0.02
- Stochastic Oscillator
- RLGT 75.61
- IMMP 95.65
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.